Reappraisal of Cardiovascular Risk Factors in Patients With Chronic Myeloproliferative Neoplasms

Abstract: Cardiovascular (CV) risk factors are important contributors to thrombotic risk in the general population and in patients with chronic myeloproliferative neoplasms (MPNs). However, the role […]

The Use of Positron Emission Tomography Imaging to Guide Radiation Therapy

Abstract: Positron emission tomography (PET)-based biologic radiation planning has the potential to improve tumor control by improving the accuracy of radiation delivery, allow for rational adaptive […]

Selecting the Optimal Radiation Modality in Prostate Cancer

Abstract: There are numerous radiation modalities for the definitive treatment of localized prostate cancer. Classic clinical trials have established the basic tenets of treatment approaches, and […]

Predicting Outcomes and Monitoring Disease in Patients With Multiple Myeloma

Abstract: Multiple myeloma (MM) is a clonal plasma cell dyscrasia and the most common form of primary bone marrow cancer. Nearly 35,000 new cases of MM […]

Acral Melanoma: Clinical Advances and Hope for the Future

Abstract: Acral melanoma is a rare subtype of melanoma with unique histologic and biologic characteristics. Given its relative rarity compared with nonacral cutaneous melanoma, acral melanoma […]

Neoadjuvant Immunotherapy in Resectable Non–Small Cell Lung Cancer

Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients […]

New Drug Approvals in Prostate Cancer and Their Effect on the Treatment Landscape

Abstract: Prostate cancer is the most frequently diagnosed non-skin cancer and the second leading cause of cancer-related mortality in men in the United States. Over the […]

Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas

Abstract: Gastric and gastroesophageal adenocarcinomas are aggressive malignancies despite current standard-of-care treatments. For patients whose tumors express human epidermal growth factor receptor 2 (HER2), HER2-targeted treatments […]

Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023

Abstract: The field of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rapidly evolving. Recent clinical developments in this ultra-rare hematologic malignancy have included the emergence of […]

Novel Approaches to the Treatment of Multiple Myeloma

Abstract: The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly […]

Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma

Abstract: The landscape for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) has continued to evolve. However, challenges continue to exist, […]

Management of Testicular Germ Cell Tumors

Abstract: Over the past half century, advancements in treatment have led to cures in an overwhelming majority of patients with testicular germ cell tumors. Astute clinical […]

Management of Toxicities Associated With Immune Checkpoint Inhibitors

Abstract: Immune-related adverse events (irAEs) encompass a diverse range of toxicities following treatment with immune checkpoint inhibitors (ICIs), each with distinctive symptoms, severities, and outcomes. irAEs […]

CAR T-Cell Therapy for CLL: A New Addition to Our Treatment Toolbox?

Abstract: Treatment of high-risk chronic lymphocytic leukemia (CLL) has undergone a revolution in recent years with the introduction of novel agents. Bruton kinase inhibitors (BTK) inhibitors, […]

The Emerging Use of Chemotherapy-Free Regimens in Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Abstract: Before the development of tyrosine kinase inhibitors (TKIs), the outcome of patients with a diagnosis of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia was dismal. Combinations […]

A Review of Essential Thrombocythemia and Its Complications

Abstract: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased platelet count in the peripheral blood and excessive megakaryopoiesis in the bone marrow. […]

Immunotherapy Treatment Landscape for Patients With Endometrial Cancer: Current Evidence and Future Opportunities

Abstract: Endometrial cancer is the most common gynecologic cancer in the United States, with a rising incidence and mortality. Traditionally, systemic treatment has included combination platinum- […]

Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms

Abstract: Grade 3 neuroendocrine neoplasms (NEN G3) are high-grade (Ki-67 index >20%) neuroendocrine malignancies that comprise both rapidly proliferating, well-differentiated neuroendocrine tumors (NET G3) and poorly […]

Ongoing Progress in BRAF-Mutated Non–Small Cell Lung Cancer

Abstract: Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non–small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated […]

The Role of Cytoreductive Surgery and Intraperitoneal Chemotherapy in Gastric Cancer

Abstract: Gastric cancer (GC) with peritoneal carcinomatosis (PC) progresses rapidly and has historically dismal survival rates. Given the aggressive tumor biology and poor survival outcomes of […]